JP2011519868A5 - - Google Patents

Download PDF

Info

Publication number
JP2011519868A5
JP2011519868A5 JP2011507707A JP2011507707A JP2011519868A5 JP 2011519868 A5 JP2011519868 A5 JP 2011519868A5 JP 2011507707 A JP2011507707 A JP 2011507707A JP 2011507707 A JP2011507707 A JP 2011507707A JP 2011519868 A5 JP2011519868 A5 JP 2011519868A5
Authority
JP
Japan
Prior art keywords
antibody
cancer
inhibitor
drug
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011507707A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519868A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/042657 external-priority patent/WO2009137378A2/en
Publication of JP2011519868A publication Critical patent/JP2011519868A/ja
Publication of JP2011519868A5 publication Critical patent/JP2011519868A5/ja
Withdrawn legal-status Critical Current

Links

JP2011507707A 2008-05-05 2009-05-04 癌を処置するための化学療法剤の連続投与 Withdrawn JP2011519868A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5040508P 2008-05-05 2008-05-05
US61/050,405 2008-05-05
PCT/US2009/042657 WO2009137378A2 (en) 2008-05-05 2009-05-04 Sequential administration of chemotherapeutic agents for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2011519868A JP2011519868A (ja) 2011-07-14
JP2011519868A5 true JP2011519868A5 (https=) 2012-06-07

Family

ID=40940448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011507707A Withdrawn JP2011519868A (ja) 2008-05-05 2009-05-04 癌を処置するための化学療法剤の連続投与

Country Status (6)

Country Link
US (1) US20110129456A1 (https=)
EP (1) EP2282739A2 (https=)
JP (1) JP2011519868A (https=)
CA (1) CA2722992A1 (https=)
MX (1) MX2010012064A (https=)
WO (1) WO2009137378A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313702B1 (ko) 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
EP1942937A1 (en) 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
AU2007342028B2 (en) 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20110104256A1 (en) * 2008-03-25 2011-05-05 Yaolin Wang Methods for treating or preventing colorectal cancer
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
NZ597692A (en) 2008-12-12 2013-08-30 Boehringer Ingelheim Int Anti-IGF antibodies
DK3000467T3 (da) 2009-04-06 2023-03-27 Wyeth Llc Behandling med neratinib mod brystkræft
EP2542155B1 (en) * 2010-03-01 2015-11-04 TAU Therapeutics LLC Method for imaging a disease
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
HRP20160305T1 (hr) 2010-10-26 2016-07-01 Mars, Incorporated Borati kao inhibitori arginaze
WO2012068339A2 (en) * 2010-11-17 2012-05-24 Glaxosmithkline Llc Methods of treating cancer
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
ES2547916T3 (es) * 2011-02-18 2015-10-09 Novartis Pharma Ag Terapia de combinación de inhibidores de mTOR/JAK
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
RU2015143490A (ru) * 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
HRP20210319T1 (hr) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije inhibitora fgfr i inhibitora igf1r
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
US10555931B2 (en) 2014-05-28 2020-02-11 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer
CN106999734B (zh) * 2014-09-29 2020-06-16 得克萨斯大学体系董事会 针对parp抑制剂的应答的预测和靶向c-met和parp1的组合疗法
EP3212670B1 (en) * 2014-10-29 2020-12-23 Five Prime Therapeutics, Inc. Combination therapy for cancer
KR102309882B1 (ko) * 2014-11-21 2021-10-06 삼성전자주식회사 c-Met 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
AU2016249981B2 (en) 2015-04-13 2022-02-17 Five Prime Therapeutics, Inc. Combination therapy for cancer
US11155555B2 (en) 2015-09-23 2021-10-26 Janssen Pharmaceutica Nv Compounds
EP3353164B1 (en) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
SG11201802961PA (en) * 2015-10-30 2018-05-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
KR102124715B1 (ko) * 2015-11-03 2020-06-18 제넨테크, 인크. 암의 치료를 위한 bcl-2 억제제 및 mek 억제제의 조합물
CN114989205A (zh) 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
CN117442747A (zh) * 2017-05-21 2024-01-26 Igf肿瘤公司 胰岛素样生长因子——用于治疗骨髓增生异常综合症的化学治疗缀合物
EP3681535A1 (en) 2017-09-13 2020-07-22 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
CN113684180B (zh) * 2021-08-31 2023-05-26 山东大学第二医院 一种提高骨髓瘤杀伤活性的nk细胞制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119069A0 (en) * 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
EP1506286B1 (en) * 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralizing human anti-igfr antibody
CA2524305C (en) * 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
DE602004029581D1 (de) * 2003-08-13 2010-11-25 Pfizer Prod Inc Modifizierte humane igf-1r antikörper
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
JP4875064B2 (ja) * 2005-04-15 2012-02-15 シェーリング コーポレイション 癌を処置または予防するための方法および組成物
AR064464A1 (es) * 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico

Similar Documents

Publication Publication Date Title
JP2011519868A5 (https=)
WO2008076278A4 (en) Methods of cancer treatment with igf1r inhibitors
JP2011515478A5 (https=)
JP2019503674A5 (https=)
RU2010120674A (ru) Полностью человеческие анти-vegf-антитела и способы их применения
JP2012247438A5 (https=)
RU2018123481A (ru) Анти-lag3 антитела и антигенсвязывающие фрагменты
US20110129456A1 (en) Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
US10544222B2 (en) PD1/CTLA4 binders
WO2010124009A2 (en) Fully human anti-vegf antibodies and methods of using
US9388239B2 (en) Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
JP2022549169A5 (https=)
CA2718918A1 (en) Methods for treating or preventing colorectal cancer
JP2014516964A5 (https=)
JP2014516964A (ja) 治療用抗igf1r合剤
JP2017538673A5 (https=)
NZ561648A (en) Methods and composition of IGF1R inhibitors for treating or preventing cancer